SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-24-000114
Filing Date
2024-08-09
Accepted
2024-08-09 09:00:23
Documents
13
Period of Report
2024-08-08
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20240808.htm   iXBRL 8-K 24989
  Complete submission text file 0001479290-24-000114.txt   147839

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20240808.xsd EX-101.SCH 1939
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20240808_lab.xml EX-101.LAB 21885
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20240808_pre.xml EX-101.PRE 12544
15 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20240808_htm.xml XML 2725
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 241190544
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)